http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 27 May 2026 05:32:46 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Intl+Ratings/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Lowered+to+JPY5%2C200+at+Citi/26552630.html Citi analyst Hidemaru Yamaguchi lowered the price target on Eisai Co Ltd. (4523:JP) (OTC: ESALY) to JPY5,200.00 (from JPY6,200.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Lowered+to+JPY5%2C200+at+Citi/26552630.html Wed, 27 May 2026 05:32:46 -0400 ESALY http://www.streetinsider.com/Analyst+PT+Change/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Lowered+to+JPY5%2C200+at+Citi/26552630.html Citi analyst Hidemaru Yamaguchi lowered the price target on Eisai Co Ltd. (4523:JP) (OTC: ESALY) to JPY5,200.00 (from JPY6,200.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Lowered+to+JPY5%2C200+at+Citi/26552630.html Wed, 27 May 2026 05:32:46 -0400 ESALY http://www.streetinsider.com/Intl+Ratings/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Lowered+to+JPY5%2C200+at+Citi/26552630.html Citi analyst Hidemaru Yamaguchi lowered the price target on Eisai Co Ltd. (4523:JP) (OTC: ESALY) to JPY5,200.00 (from JPY6,200.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Lowered+to+JPY5%2C200+at+Citi/26552630.html Wed, 27 May 2026 05:32:46 -0400 ESALY http://www.streetinsider.com/Analyst+PT+Change/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Lowered+to+JPY5%2C200+at+Citi/26552630.html Citi analyst Hidemaru Yamaguchi lowered the price target on Eisai Co Ltd. (4523:JP) (OTC: ESALY) to JPY5,200.00 (from JPY6,200.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Lowered+to+JPY5%2C200+at+Citi/26552630.html Wed, 27 May 2026 05:32:46 -0400 ESALY http://www.streetinsider.com/Intl+Ratings/Macquarie+Reiterates+Outperform+Rating+on+Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29/26545832.html <p>Macquarie analyst Candyce Gao reiterated an Outperform rating and JPY5,500.00 price target on Eisai Co Ltd. (4523:JP) (OTC: ESALY).</p> http://www.streetinsider.com/Intl+Ratings/Macquarie+Reiterates+Outperform+Rating+on+Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29/26545832.html Tue, 26 May 2026 07:19:33 -0400 ESALY http://www.streetinsider.com/Intl+Ratings/Macquarie+Reiterates+Outperform+Rating+on+Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29/26545832.html <p>Macquarie analyst Candyce Gao reiterated an Outperform rating and JPY5,500.00 price target on Eisai Co Ltd. (4523:JP) (OTC: ESALY).</p> http://www.streetinsider.com/Intl+Ratings/Macquarie+Reiterates+Outperform+Rating+on+Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29/26545832.html Tue, 26 May 2026 07:19:33 -0400 ESALY http://www.streetinsider.com/Intl+Ratings/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Raised+to+JPY5%2C100+at+JPMorgan/26178118.html JPMorgan analyst Seiji Wakao raised the price target on Eisai Co Ltd. (4523:JP) (OTC: ESALY) to JPY5,100.00 (from JPY4,900.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Raised+to+JPY5%2C100+at+JPMorgan/26178118.html Wed, 18 Mar 2026 05:46:18 -0400 ESALY http://www.streetinsider.com/Analyst+PT+Change/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Raised+to+JPY5%2C100+at+JPMorgan/26178118.html JPMorgan analyst Seiji Wakao raised the price target on Eisai Co Ltd. (4523:JP) (OTC: ESALY) to JPY5,100.00 (from JPY4,900.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Raised+to+JPY5%2C100+at+JPMorgan/26178118.html Wed, 18 Mar 2026 05:46:18 -0400 ESALY http://www.streetinsider.com/Intl+Ratings/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Raised+to+JPY5%2C100+at+JPMorgan/26178118.html JPMorgan analyst Seiji Wakao raised the price target on Eisai Co Ltd. (4523:JP) (OTC: ESALY) to JPY5,100.00 (from JPY4,900.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Raised+to+JPY5%2C100+at+JPMorgan/26178118.html Wed, 18 Mar 2026 05:46:18 -0400 ESALY http://www.streetinsider.com/Analyst+PT+Change/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Raised+to+JPY5%2C100+at+JPMorgan/26178118.html JPMorgan analyst Seiji Wakao raised the price target on Eisai Co Ltd. (4523:JP) (OTC: ESALY) to JPY5,100.00 (from JPY4,900.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Raised+to+JPY5%2C100+at+JPMorgan/26178118.html Wed, 18 Mar 2026 05:46:18 -0400 ESALY http://www.streetinsider.com/Intl+Ratings/UBS+Starts+Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+at+Neutral/25889587.html <p>UBS analyst Atsushi Seki initiates coverage on Eisai Co Ltd. (4523:JP) (OTC: ESALY) with a Neutral rating and a price target of JPY4,850.00.</p><p>The analyst comments: "Market expectations for Leqembi, which achieved slowing of Alzheimer’s disease progression, have moderated, and we are now in a phase where commercial rollout, early-patient AHEAD 3-45 trial, and anti-tau antibody etalanetug expectations are priced in. While Leqembi revenue is expanding on broader blood biomarker adoption and reimbursement, the profit contribution is limited due to profit-sharing with Biogen, and the consensus FY3/27 PER of 24X does not appear cheap. Eisai has a strategic advantage with Leqembi http://www.streetinsider.com/Intl+Ratings/UBS+Starts+Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+at+Neutral/25889587.html Mon, 26 Jan 2026 05:25:18 -0400 ESALY http://www.streetinsider.com/New+Coverage/UBS+Starts+Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+at+Neutral/25889587.html <p>UBS analyst Atsushi Seki initiates coverage on Eisai Co Ltd. (4523:JP) (OTC: ESALY) with a Neutral rating and a price target of JPY4,850.00.</p><p>The analyst comments: "Market expectations for Leqembi, which achieved slowing of Alzheimer’s disease progression, have moderated, and we are now in a phase where commercial rollout, early-patient AHEAD 3-45 trial, and anti-tau antibody etalanetug expectations are priced in. While Leqembi revenue is expanding on broader blood biomarker adoption and reimbursement, the profit contribution is limited due to profit-sharing with Biogen, and the consensus FY3/27 PER of 24X does not appear cheap. Eisai has a strategic advantage with Leqembi http://www.streetinsider.com/New+Coverage/UBS+Starts+Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+at+Neutral/25889587.html Mon, 26 Jan 2026 05:25:18 -0400 ESALY http://www.streetinsider.com/Analyst+Comments/UBS+Starts+Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+at+Neutral/25889587.html <p>UBS analyst Atsushi Seki initiates coverage on Eisai Co Ltd. (4523:JP) (OTC: ESALY) with a Neutral rating and a price target of JPY4,850.00.</p><p>The analyst comments: "Market expectations for Leqembi, which achieved slowing of Alzheimer’s disease progression, have moderated, and we are now in a phase where commercial rollout, early-patient AHEAD 3-45 trial, and anti-tau antibody etalanetug expectations are priced in. While Leqembi revenue is expanding on broader blood biomarker adoption and reimbursement, the profit contribution is limited due to profit-sharing with Biogen, and the consensus FY3/27 PER of 24X does not appear cheap. Eisai has a strategic advantage with Leqembi http://www.streetinsider.com/Analyst+Comments/UBS+Starts+Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+at+Neutral/25889587.html Mon, 26 Jan 2026 05:25:18 -0400 ESALY http://www.streetinsider.com/Intl+Ratings/UBS+Starts+Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+at+Neutral/25889587.html <p>UBS analyst Atsushi Seki initiates coverage on Eisai Co Ltd. (4523:JP) (OTC: ESALY) with a Neutral rating and a price target of JPY4,850.00.</p><p>The analyst comments: "Market expectations for Leqembi, which achieved slowing of Alzheimer’s disease progression, have moderated, and we are now in a phase where commercial rollout, early-patient AHEAD 3-45 trial, and anti-tau antibody etalanetug expectations are priced in. While Leqembi revenue is expanding on broader blood biomarker adoption and reimbursement, the profit contribution is limited due to profit-sharing with Biogen, and the consensus FY3/27 PER of 24X does not appear cheap. Eisai has a strategic advantage with Leqembi http://www.streetinsider.com/Intl+Ratings/UBS+Starts+Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+at+Neutral/25889587.html Mon, 26 Jan 2026 05:25:18 -0400 ESALY http://www.streetinsider.com/New+Coverage/UBS+Starts+Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+at+Neutral/25889587.html <p>UBS analyst Atsushi Seki initiates coverage on Eisai Co Ltd. (4523:JP) (OTC: ESALY) with a Neutral rating and a price target of JPY4,850.00.</p><p>The analyst comments: "Market expectations for Leqembi, which achieved slowing of Alzheimer’s disease progression, have moderated, and we are now in a phase where commercial rollout, early-patient AHEAD 3-45 trial, and anti-tau antibody etalanetug expectations are priced in. While Leqembi revenue is expanding on broader blood biomarker adoption and reimbursement, the profit contribution is limited due to profit-sharing with Biogen, and the consensus FY3/27 PER of 24X does not appear cheap. Eisai has a strategic advantage with Leqembi http://www.streetinsider.com/New+Coverage/UBS+Starts+Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+at+Neutral/25889587.html Mon, 26 Jan 2026 05:25:18 -0400 ESALY http://www.streetinsider.com/Analyst+Comments/UBS+Starts+Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+at+Neutral/25889587.html <p>UBS analyst Atsushi Seki initiates coverage on Eisai Co Ltd. (4523:JP) (OTC: ESALY) with a Neutral rating and a price target of JPY4,850.00.</p><p>The analyst comments: "Market expectations for Leqembi, which achieved slowing of Alzheimer’s disease progression, have moderated, and we are now in a phase where commercial rollout, early-patient AHEAD 3-45 trial, and anti-tau antibody etalanetug expectations are priced in. While Leqembi revenue is expanding on broader blood biomarker adoption and reimbursement, the profit contribution is limited due to profit-sharing with Biogen, and the consensus FY3/27 PER of 24X does not appear cheap. Eisai has a strategic advantage with Leqembi http://www.streetinsider.com/Analyst+Comments/UBS+Starts+Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+at+Neutral/25889587.html Mon, 26 Jan 2026 05:25:18 -0400 ESALY http://www.streetinsider.com/Intl+Ratings/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Lowered+to+JPY4%2C750+at+Goldman+Sachs/25749827.html Goldman Sachs analyst Akinori Ueda lowered the price target on Eisai Co Ltd. (4523:JP) (OTC: ESALY) to JPY4,750.00 (from JPY5,500.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Lowered+to+JPY4%2C750+at+Goldman+Sachs/25749827.html Wed, 17 Dec 2025 07:08:22 -0400 ESALY http://www.streetinsider.com/Analyst+PT+Change/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Lowered+to+JPY4%2C750+at+Goldman+Sachs/25749827.html Goldman Sachs analyst Akinori Ueda lowered the price target on Eisai Co Ltd. (4523:JP) (OTC: ESALY) to JPY4,750.00 (from JPY5,500.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Lowered+to+JPY4%2C750+at+Goldman+Sachs/25749827.html Wed, 17 Dec 2025 07:08:22 -0400 ESALY http://www.streetinsider.com/Intl+Ratings/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Lowered+to+JPY4%2C750+at+Goldman+Sachs/25749827.html Goldman Sachs analyst Akinori Ueda lowered the price target on Eisai Co Ltd. (4523:JP) (OTC: ESALY) to JPY4,750.00 (from JPY5,500.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Lowered+to+JPY4%2C750+at+Goldman+Sachs/25749827.html Wed, 17 Dec 2025 07:08:22 -0400 ESALY http://www.streetinsider.com/Analyst+PT+Change/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Lowered+to+JPY4%2C750+at+Goldman+Sachs/25749827.html Goldman Sachs analyst Akinori Ueda lowered the price target on Eisai Co Ltd. (4523:JP) (OTC: ESALY) to JPY4,750.00 (from JPY5,500.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Lowered+to+JPY4%2C750+at+Goldman+Sachs/25749827.html Wed, 17 Dec 2025 07:08:22 -0400 ESALY http://www.streetinsider.com/Intl+Ratings/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Raised+to+JPY5%2C500+at+Macquarie/25449727.html Macquarie analyst Candyce Gao raised the price target on Eisai Co Ltd. (4523:JP) (OTC: ESALY) to JPY5,500.00 (from JPY5,000.00) while maintaining a Outperform rating. http://www.streetinsider.com/Intl+Ratings/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Raised+to+JPY5%2C500+at+Macquarie/25449727.html Tue, 14 Oct 2025 06:36:33 -0400 ESALY http://www.streetinsider.com/Analyst+PT+Change/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Raised+to+JPY5%2C500+at+Macquarie/25449727.html Macquarie analyst Candyce Gao raised the price target on Eisai Co Ltd. (4523:JP) (OTC: ESALY) to JPY5,500.00 (from JPY5,000.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Raised+to+JPY5%2C500+at+Macquarie/25449727.html Tue, 14 Oct 2025 06:36:33 -0400 ESALY http://www.streetinsider.com/Intl+Ratings/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Raised+to+JPY5%2C500+at+Macquarie/25449727.html Macquarie analyst Candyce Gao raised the price target on Eisai Co Ltd. (4523:JP) (OTC: ESALY) to JPY5,500.00 (from JPY5,000.00) while maintaining a Outperform rating. http://www.streetinsider.com/Intl+Ratings/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Raised+to+JPY5%2C500+at+Macquarie/25449727.html Tue, 14 Oct 2025 06:36:33 -0400 ESALY http://www.streetinsider.com/Analyst+PT+Change/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Raised+to+JPY5%2C500+at+Macquarie/25449727.html Macquarie analyst Candyce Gao raised the price target on Eisai Co Ltd. (4523:JP) (OTC: ESALY) to JPY5,500.00 (from JPY5,000.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Raised+to+JPY5%2C500+at+Macquarie/25449727.html Tue, 14 Oct 2025 06:36:33 -0400 ESALY http://www.streetinsider.com/Intl+Ratings/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Raised+to+JPY6%2C200+at+Citi/25326795.html Citi analyst Hidemaru Yamaguchi raised the price target on Eisai Co Ltd. (4523:JP) (OTC: ESALY) to JPY6,200.00 (from JPY5,900.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Eisai+Co+Ltd.+%284523%3AJP%29+%28ESALY%29+PT+Raised+to+JPY6%2C200+at+Citi/25326795.html Fri, 12 Sep 2025 02:51:38 -0400 ESALY